FOLH1 and prostate carcinoma: A phase I multicenter study of PSMA-ADC was designed to identify the maximum tolerated dose (MTD) and DLT in patients with progressive metastatic castration-resistance prostate cancer who had received prior taxane-based chemotherapy [16].